SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Cornelissen Jan) srt2:(2005-2009)"

Sökning: WFRF:(Cornelissen Jan) > (2005-2009)

  • Resultat 1-4 av 4
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Cornelissen, Gerard, et al. (författare)
  • Transport of polycyclic aromatic hydrocarbons and polychlorinated biphenyls in a landfill : A novel equilibrium passive sampler to determine free and total dissolved concentrations in leachate water
  • 2009
  • Ingår i: Journal of Hydrology. - : Elsevier BV. - 0022-1694 .- 1879-2707. ; 369:04-mar, s. 253-259
  • Tidskriftsartikel (refereegranskat)abstract
    • Equilibrium passive sampling devices consisting of 17-mu m thick polyoxymethylene (POM) were in situ deployed as a novel technique for landfill groundwater leachate water sampling of freely dissolved poly-cyclic aromatic hydrocarbons (PAHs) and polychlorinated biphenyls (PCBs). POM was deployed in two groundwater leachate wells (flow around 100 m y(-1)) and an effluent leachate tank. The dissipation of >90% of spiked performance reference compounds and comparison between 60 d and 140 d of equilibration confirmed that POM-water equilibrium was reached for all PAHs and most PCBs within 60 d. Comparison of total and freely dissolved concentrations yielded dissolved organic carbon-water distribution ratios that were on average 0.4 log-unit below amorphous organic carbon-water distribution ratios and in accordance with literature values. Particle-bound fractions ranged from 50% (small PAHs) to 99.9% (large PCBs), and were >95% for most compounds. It was concluded that POM-17 equilibrium passive samplers provide a facile method to measure freely dissolved concentrations of PAH and PCB in groundwater leachate, which will yield valuable information on its ecotoxicological risk for aquatic and benthic organisms. 
  •  
2.
  • Druker, Brian J., et al. (författare)
  • Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
  • 2006
  • Ingår i: New England Journal of Medicine. - 0028-4793 .- 1533-4406. ; 355:23, s. 2408-2417
  • Tidskriftsartikel (refereegranskat)abstract
    • BACKGROUND: The cause of chronic myeloid leukemia (CML) is a constitutively active BCR-ABL tyrosine kinase. Imatinib inhibits this kinase, and in a short-term study was superior to interferon alfa plus cytarabine for newly diagnosed CML in the chronic phase. For 5 years, we followed patients with CML who received imatinib as initial therapy. METHODS: We randomly assigned 553 patients to receive imatinib and 553 to receive interferon alfa plus cytarabine and then evaluated them for overall and event-free survival; progression to accelerated-phase CML or blast crisis; hematologic, cytogenetic, and molecular responses; and adverse events. RESULTS: The median follow-up was 60 months. Kaplan-Meier estimates of cumulative best rates of complete cytogenetic response among patients receiving imatinib were 69% by 12 months and 87% by 60 months. An estimated 7% of patients progressed to accelerated-phase CML or blast crisis, and the estimated overall survival of patients who received imatinib as initial therapy was 89% at 60 months. Patients who had a complete cytogenetic response or in whom levels of BCR-ABL transcripts had fallen by at least 3 log had a significantly lower risk of disease progression than did patients without a complete cytogenetic response (P<0.001). Grade 3 or 4 adverse events diminished over time, and there was no clinically significant change in the profile of adverse events. CONCLUSIONS: After 5 years of follow-up, continuous treatment of chronic-phase CML with imatinib as initial therapy was found to induce durable responses in a high proportion of patients. (ClinicalTrials.gov number, NCT00006343 [ClinicalTrials.gov].)
  •  
3.
  •  
4.
  • Stevens, Jan, 1955, et al. (författare)
  • Wiskundig onderzoek per computer?
  • 2009
  • Ingår i: Nieuw Archief voor Wiskunde. - 0028-9825. ; (5) 10:3, s. 197-200
  • Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-4 av 4
Typ av publikation
tidskriftsartikel (3)
konferensbidrag (1)
Typ av innehåll
refereegranskat (3)
övrigt vetenskapligt/konstnärligt (1)
Författare/redaktör
Cornelissen, Jan J (2)
Cornelissen, Gerard (1)
Malm, Claes (1)
Perez Simon, Jose An ... (1)
Martino, Rodrigo (1)
Stone, Richard M. (1)
visa fler...
Simonsson, Bengt (1)
Mohty, Mohamad (1)
Stevens, Jan, 1955 (1)
Fischer, Thomas (1)
Socié, Gérard (1)
Baccarani, Michele (1)
Saglio, Giuseppe (1)
Cervantes, Francisco (1)
Gratwohl, Alois (1)
Guilhot, François (1)
Hochhaus, Andreas (1)
Hughes, Timothy (1)
Kantarjian, Hagop (1)
Silver, Richard T. (1)
Nagler, Arnon (1)
Larson, Richard A. (1)
Radich, Jerald P. (1)
Rousselot, Philippe (1)
Goldman, John M. (1)
Labopin, Myriam (1)
Basara, Nadezda (1)
Rocha, Vanderson (1)
Breedveld, Gijsbert ... (1)
Okkenhaug, Gudny (1)
Sorlie, Jan-Erik (1)
Druker, Brian J. (1)
O'Brien, Stephen G. (1)
Gathmann, Insa (1)
Gattermann, Norbert (1)
Deininger, Michael W ... (1)
Powell, Bayard L. (1)
Gabrilove, Janice L. (1)
Reiffers, Josy (1)
Agis, Hermine (1)
Verhoef, Gregor (1)
Shepherd, John (1)
Nielsen, Johan L. (1)
Taylor, Kerry (1)
So, Charlene (1)
Letvak, Laurie (1)
Eder, Matthias (1)
Polge, Emmanuelle (1)
Kroger, Nicolaus (1)
Tabrizi, Reza (1)
visa färre...
Lärosäte
Göteborgs universitet (1)
Uppsala universitet (1)
Stockholms universitet (1)
Linköpings universitet (1)
Chalmers tekniska högskola (1)
Språk
Engelska (3)
Nederländska (1)
Forskningsämne (UKÄ/SCB)
Naturvetenskap (2)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy